ClarityAccessHub — The Patient Access Network for Memory Care
ClarityAccessHub is the patient access network purpose-built for anti-amyloid therapy delivery. Through the Memory Rx Toolkit and the CerebraLinked platform, we operationalize the therapy readiness, site-of-care, monitoring, and registry workflow that anti-amyloid therapy requires — so patients diagnosed with Alzheimer's can actually be treated.
A patient access network purpose-built for anti-amyloid therapy delivery. We connect and coordinate infusion centers administering Leqembi and Kisunla — and the AD therapies coming behind them — into a single credentialed delivery network.
The disease-specific operational implementation for anti-amyloid therapy. The clinical, compliance, and registry infrastructure that AD therapy delivery requires — built around the actual workflow of qualifying and treating AD patients.
The technology platform inside the Memory Rx Toolkit. Four-pillar AD workflow — diagnosis routing, therapy readiness coordination, site-of-care coordination, payer coordination — plus the registry layer that anti-amyloid therapy requires.
Why ClarityAccessHub Exists
In 2023, manufacturers laid out the infrastructure that would be needed for anti-amyloid drugs to reach patients. In 2026, the data confirms what happens when that infrastructure isn't built.
The Thesis — 2023
A five-year projection of $7.5B in US anti-amyloid sales.
Anchored on the assumption that practices would build the diagnostic capability, the referral protocols, the infusion availability, and the coordination layer the therapies require.
Five infrastructure gaps identified.
Limited advanced diagnostics. Lack of early diagnosis and referral protocols. Barriers to diagnostic access. Inadequate infusion availability. Limited in-house patient support and coordination.
Manufacturers don't build the channel.
The channel was always going to require a third-party operator with the relationships, the platform, and the patient access model to make complex coordination work.
The Reality — 2026
Less than 20% of forecast revenue.
Three years after launch, actual combined Medicare Part B spending on anti-amyloid therapies is running at less than 20% of the original CMS actuarial projection.
Around 19,000 patients on treatment.
Out of approximately 6.5 million Americans living with Alzheimer's disease. Top-tier academic AD programs are maxed at low hundreds of patients.
Most infusion centers don't participate.
The bottleneck isn't demand or efficacy. The bottleneck is that practices don't have the infrastructure, the economics, or the compliance support to administer these therapies at network scale.
Who ClarityAccessHub Serves
ClarityAccessHub works alongside the existing neurology practices, physician aggregators, and infusion networks that already serve AD patients — providing the AD-specific delivery infrastructure none of them is built to operate alone.
ClarityAccessHub partners with anti-amyloid manufacturers through service agreements and data agreements — structured commercial relationships that fund the AD delivery infrastructure your therapies need at network scale.
See the manufacturer offeringInfusion centers join ClarityAccessHub to access the Memory Rx Toolkit, manufacturer-funded coordination support, and the operational infrastructure that makes anti-amyloid therapy viable at network scale.
See the member offeringNeurology practices that diagnose and qualify AD patients but prefer not to infuse in-house can refer patients to ClarityAccessHub's credentialed AIC network. We handle the AD complexity; the patient stays under your continuing care.
For referring neurologyFor manufacturer partnerships, provider membership inquiries, or general questions about ClarityAccessHub and the Memory Rx Toolkit.
Contact ClarityAccessHub